Ameritas Advisory Services LLC Buys 90,384 Shares of Pfizer Inc. $PFE

Ameritas Advisory Services LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 241.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 127,869 shares of the biopharmaceutical company’s stock after buying an additional 90,384 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Pfizer were worth $3,184,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Triad Wealth Partners LLC lifted its position in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares during the period. ETF Store Inc. increased its stake in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its stake in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC lifted its holdings in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the last quarter. Finally, Quest Investment Management LLC boosted its position in shares of Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 405 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.3%

Pfizer stock opened at $25.96 on Thursday. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The stock has a fifty day simple moving average of $27.03 and a two-hundred day simple moving average of $26.19. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market cap of $147.93 billion, a price-to-earnings ratio of 19.81 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the company posted $0.92 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A and B patients with inhibitors, a label expansion that could help broaden future sales. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
• Positive Sentiment: Analyst coverage highlighted Pfizer’s rebound story, with the company targeting high-single-digit revenue CAGR from 2029 as new launches, acquisitions, and pipeline growth may offset patent-expiration headwinds. Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
• Positive Sentiment: Multiple market commentators argued Pfizer looks undervalued after recent earnings, with some calling it a possible long-term buying opportunity and noting healthy underlying results despite a muted reaction. Top Analyst Reports for Meta, Pfizer & Salesforce
• Neutral Sentiment: Pfizer and partner Arvinas licensed VEPPANU (vepdegestrant) rights to Rigel Pharmaceuticals, bringing Pfizer $85 million in upfront and transition payments plus potential milestones and royalties, but also ceding commercialization control. Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
• Negative Sentiment: Bearish commentary continued to focus on Pfizer’s post-pandemic slowdown, with articles questioning dividend sustainability and whether the company can regain stronger growth as older products face loss of exclusivity. Pfizer’s Net Income Drops in Q1. Is Its Dividend Still Safe?
• Negative Sentiment: Broader sector coverage also pointed to tougher vaccine demand conditions in the U.S., which could weigh on sentiment toward large pharma names including Pfizer. How tough is it getting for vaccine makers in the U.S.?

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. CICC Research started coverage on Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. Barclays started coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.74.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.